These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 17153653)
1. c-erbB-2 oncoprotein over-expression in breast cancer and its relationship to histology and grade in a Ugandan population. Nalwoga H; Odida M; Wabinga H East Afr Med J; 2006 Aug; 83(8):411-5. PubMed ID: 17153653 [TBL] [Abstract][Full Text] [Related]
2. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre. Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345 [TBL] [Abstract][Full Text] [Related]
3. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein. Looi LM; Cheah PL Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast. Sharma BK; Ray A; Kaur S; Gupta S Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149 [TBL] [Abstract][Full Text] [Related]
5. Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix. Ray A; Naik SL; Sharma BK Indian J Physiol Pharmacol; 2002 Oct; 46(4):423-33. PubMed ID: 12683217 [TBL] [Abstract][Full Text] [Related]
6. Schirrous invasive ductal carcinoma of the breast overexpress p53 oncoprotein. Ferrini FS; Rossi MA; Neto MM; Soares FA Sao Paulo Med J; 2001 Jan; 119(1):4-6. PubMed ID: 11175617 [TBL] [Abstract][Full Text] [Related]
7. p185 overexpression in 220 samples of breast cancer undergoing primary surgery: comparison with c-erbB-2 gene amplification. Dalifard I; Daver A; Goussard J; Lorimier G; Gosse-Brun S; Lortholary A; Larra F Int J Mol Med; 1998 May; 1(5):855-61. PubMed ID: 9852307 [TBL] [Abstract][Full Text] [Related]
8. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer. Coene ED; Schelfhout V; Winkler RA; Schelfhout AM; Van Roy N; Grooteclaes M; Speleman F; De Potter CR Virchows Arch; 1997 May; 430(5):365-72. PubMed ID: 9174626 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer. Horiguchi J; Iino Y; Takei H; Yokoe T; Ishida T; Morishita Y Oncology; 1994; 51(1):47-51. PubMed ID: 7903441 [TBL] [Abstract][Full Text] [Related]
10. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Riou G; Mathieu MC; Barrois M; Le Bihan ML; Ahomadegbe JC; Bénard J; Lê MG Int J Cancer; 2001 Jul; 95(4):266-70. PubMed ID: 11400121 [TBL] [Abstract][Full Text] [Related]
11. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pinto AE; André S; Laranjeira C; Soares J Pathology; 2005 Feb; 37(1):45-50. PubMed ID: 15875733 [TBL] [Abstract][Full Text] [Related]
12. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. Gasparini G; Gullick WJ; Bevilacqua P; Sainsbury JR; Meli S; Boracchi P; Testolin A; La Malfa G; Pozza F J Clin Oncol; 1992 May; 10(5):686-95. PubMed ID: 1349034 [TBL] [Abstract][Full Text] [Related]
13. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays? Selvarajan S; Tan SY; Sii LH; Tan PH Pathology; 2006 Aug; 38(4):316-20. PubMed ID: 16916720 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors. Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176 [TBL] [Abstract][Full Text] [Related]
15. Correlation between histological grade and c-erbB2 oncoprotein overexpression in infiltrating ductal carcinoma of breast. Looi LM; Cheah PL; Yap SF Malays J Pathol; 1997 Jun; 19(1):35-9. PubMed ID: 10879240 [TBL] [Abstract][Full Text] [Related]
16. [Immunohistochemical study of oncogene c-erbb-2 expression and extracellular matrix proteins in breast cancer (various mechanisms of invasion)]. Pozharisskiĭi KM; Kyshtoobaeva ASh; Turkevich EA Arkh Patol; 1997; 59(4):19-25. PubMed ID: 9334150 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of c-erbB-2 oncoprotein and EGF-R in pre- and postmenopausal breast cancer. Ratnakar N; Sharma BK; Chaturvedi KU; Kaur S; Naik SL; Ray A APMIS; 1998 Nov; 106(11):1075-80. PubMed ID: 9890270 [TBL] [Abstract][Full Text] [Related]
18. C-erbB-2 overexpression and survival in early onset breast cancer. Agrup M; Stål O; Olsen K; Wingren S Breast Cancer Res Treat; 2000 Sep; 63(1):23-9. PubMed ID: 11079156 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Morote J; de Torres I; Caceres C; Vallejo C; Schwartz S; Reventos J Int J Cancer; 1999 Aug; 84(4):421-5. PubMed ID: 10404097 [TBL] [Abstract][Full Text] [Related]
20. c-erbB-2 oncoprotein is not an independent prognostic parameter in primary breast carcinoma. An immunohistochemical study. Haerslev T; Jacobsen GK APMIS; 1994 Aug; 102(8):612-22. PubMed ID: 7946263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]